Objective: Asprosin, a new adipocytokine, has been reported to be related with glucose release, dyslipidemia and insulin resistance (IR). However, the relationship of asprosin with metabolic syndrome (MetS) remains unknown. This study aims to investigate serum asprosin levels in MetS as well as its association with various metabolic parameters in humans.
Methods: The consecutive 131 patients with MetS and age-matched 162 healthy subjects were recruited for this study. Serum asprosin concentrations were determined by ELISA. Lipid profile, glucose, insulin, and inflammatory markers were also measured.
Results: Serum asprosin levels were higher in subjects with MetS 23.52 (16.70, 32.05) ng/ml compared to 16.70 (12.87, 22.38) ng/ml in the controls (P < 0.01), and showed an increasing trend with the increased numbers of metabolic components (P for trend < 0.01). In all studied subjects, serum asprosin levels were positive correlated with body mass index, waist circumference, percentage of body fat (%), triglyceride, fasting plasma glucose, 2h plasma glucose, fasting insulin, HOMA-IR, interleukin (IL) -6 and monocyte chemoattractant protein (MCP)-1, and negative correlated with HDL cholesterol (P < 0.05). In a multiple linear regression, asprosin was independently and positively correlated with triglyceride and HOMA-IR (P < 0.05). Binary logistic regression revealed that asprosin was independently and positively correlated with the occurrence of MetS and IR even after controlling for anthropometric variables, lipid profiles and inflammatory markers.
Conclusion: Asprosin may be a metabolic - related adipokine and related to insulin resistance and MetS.
Trial Registration: ChiCTR, ChiCTR1800018347. Registered 12 September 2018, http://www.chictr.org.cn/showproj.aspx?proj=31050.
Figure 1
Figure 2
This is a list of supplementary files associated with this preprint. Click to download.
Loading...
Posted 14 Aug, 2020
Posted 14 Aug, 2020
Objective: Asprosin, a new adipocytokine, has been reported to be related with glucose release, dyslipidemia and insulin resistance (IR). However, the relationship of asprosin with metabolic syndrome (MetS) remains unknown. This study aims to investigate serum asprosin levels in MetS as well as its association with various metabolic parameters in humans.
Methods: The consecutive 131 patients with MetS and age-matched 162 healthy subjects were recruited for this study. Serum asprosin concentrations were determined by ELISA. Lipid profile, glucose, insulin, and inflammatory markers were also measured.
Results: Serum asprosin levels were higher in subjects with MetS 23.52 (16.70, 32.05) ng/ml compared to 16.70 (12.87, 22.38) ng/ml in the controls (P < 0.01), and showed an increasing trend with the increased numbers of metabolic components (P for trend < 0.01). In all studied subjects, serum asprosin levels were positive correlated with body mass index, waist circumference, percentage of body fat (%), triglyceride, fasting plasma glucose, 2h plasma glucose, fasting insulin, HOMA-IR, interleukin (IL) -6 and monocyte chemoattractant protein (MCP)-1, and negative correlated with HDL cholesterol (P < 0.05). In a multiple linear regression, asprosin was independently and positively correlated with triglyceride and HOMA-IR (P < 0.05). Binary logistic regression revealed that asprosin was independently and positively correlated with the occurrence of MetS and IR even after controlling for anthropometric variables, lipid profiles and inflammatory markers.
Conclusion: Asprosin may be a metabolic - related adipokine and related to insulin resistance and MetS.
Trial Registration: ChiCTR, ChiCTR1800018347. Registered 12 September 2018, http://www.chictr.org.cn/showproj.aspx?proj=31050.
Figure 1
Figure 2
Loading...